Last reviewed · How we verify
LY3316531
At a glance
| Generic name | LY3316531 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3316531 in Healthy Participants (PHASE1)
- A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3316531 CI brief — competitive landscape report
- LY3316531 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI